Welcome to our dedicated page for Viemed Healthcare news (Ticker: VMD), a resource for investors and traders seeking the latest updates and insights on Viemed Healthcare stock.
The Viemed Healthcare, Inc. (VMD) news page on Stock Titan aggregates company-specific updates for investors and observers who follow in-home post-acute respiratory care and home medical equipment providers. Viemed’s public communications describe it as a national leader in technology-enabled, in-home clinical care focused on non-invasive ventilation and related respiratory therapies in the United States.
News items for Viemed commonly include quarterly and year-to-date financial results, where the company reports revenue, net income, adjusted EBITDA, cash flow, and balance sheet data. These earnings releases, often furnished to the SEC on Form 8-K, are accompanied by financial supplements and sometimes updated full-year guidance ranges. They also highlight trends in ventilator, PAP therapy, and sleep resupply patient counts, as well as commentary from management on operating performance.
Another important category of news involves strategic transactions and capital allocation. Recent press releases have covered the authorization and completion of a share repurchase program, including the total number of shares repurchased and aggregate purchase price. Viemed has also announced the completion of its acquisition of Lehan’s Medical Equipment, an Illinois-based provider of home medical equipment with a focus on women’s health products and respiratory devices, and has discussed how this acquisition fits within its broader platform.
Visitors to this page can also expect updates about credit facility amendments, investor presentations, and conference appearances, which are often disclosed through Form 8-K filings and press releases. Together, these news items provide a view into Viemed’s operating trends, service diversification, financing arrangements, and outreach to the investment community. For anyone tracking VMD, this page serves as a centralized feed of the company’s official announcements and related coverage.
Viemed Healthcare reported strong Q3 2024 financial results with net revenues increasing 17.4% to $58.0 million, setting a company record. Net income rose 33% to $3.9 million ($0.10 per diluted share), while Adjusted EBITDA grew 15.5% to $14.0 million. The company expanded its ventilator patient count by 11.0% to 11,374 and increased sleep therapy patients by 11.0% to 19,478. With a strong cash balance of $11.3 million and $55.3 million available in credit facilities, Viemed projects Q4 2024 revenues between $59.7-60.9 million, exceeding previous guidance.
Viemed Healthcare, a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming third quarter 2024 earnings conference call. The call is scheduled for Thursday, November 7, 2024, at 12:00 p.m. EST.
Interested parties can participate in the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International). A live audio webcast will also be available. Following the live call, a replay will be accessible in the Investor Relations section of Viemed's website at www.viemed.com.
Viemed Healthcare (NASDAQ:VMD) reported record second quarter 2024 financial results, with net revenues reaching $55.0 million, a 27% increase year-over-year and 9% sequential growth. The company achieved a net income of $1.5 million and Adjusted EBITDA of $12.8 million, up 31% from Q2 2023. Viemed's ventilator patient count grew to 10,905, a 4.4% sequential increase. The company maintains a strong financial position with $8.8 million in cash and $13.5 million in working capital. For Q3 2024, Viemed expects net revenues between $56.5 million and $57.7 million. CEO Casey Hoyt emphasized the company's strategy validation and leading position in complex respiratory care services.
Viemed Healthcare, a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming Quarterly Conference Call. The call is scheduled for Thursday, August 8, 2024, at 11:00 a.m. ET.
Interested parties can participate by dialing 888-437-3179 (US Toll-Free) or +1 862-298-0702 (International). Financial professionals are invited to pre-register by emailing investorinfo@viemed.com by 12:00 p.m. ET on Wednesday, August 7, 2024, to ask questions during the call.
A live audio webcast will be available, and following the call, a replay can be accessed in the Investor Relations section of Viemed's website.
Viemed Healthcare, Inc. announced its first quarter 2024 financial results, reporting net revenues of $50.6 million, a 28% increase from the same quarter last year. The company achieved a net income of $1.6 million and adjusted EBITDA of $10.1 million. Viemed also has a strong cash balance of $7.3 million, no net debt, and approximately $53 million available under credit facilities. The recent strategic partnership with East Alabama Health is expected to generate net revenues of $53.8-$54.8 million in the second quarter of 2024. CEO Casey Hoyt expressed optimism about the company's performance, highlighting investments in personnel, operational enhancements, and acquisition strategies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.